drugset / Trial / NCT02408484

Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

NCT02408484

Phase 3 Completed 15 enrolled Octapharma
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the efficacy of Octafibrin, a fibrinogen concentrate in in the on-demand treatment of spontaneous or traumatic bleeding episodes in paediatric patients less than 12 years of age.The planned study duration is up to 5 years. The study will be considered completed when a minimum of 6 subjects (i.e., at least 3 subjects aged between 0 and \<6 years and 3 subjects aged between 6 and \<12 years) have at least one documented bleeding episode and when in total a minimum of 2 surgical procedures have been performed. All patients will undergo a pharmacokinetic (PK) study after screening. This will have a duration of 14 days, after which a patient can be treated for a bleeding episode or planned surgical procedure when they occur.

Timeline

Start
2015-12
Primary completion
2019-06-11
Completion
2019-06-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Octafibrin Protein / enzyme biologic